Zelluna ASA Logo

Zelluna ASA

Develops off-the-shelf, TCR-guided NK cell immunotherapies for solid cancers.

ULTI | OL

Overview

Corporate Details

ISIN(s):
NO0010851603
LEI:
254900B4VALJZR9TL744
Country:
Norway
Address:
Ullernchausseen 64, 0379 Oslo

Description

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-12 13:02
Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to …
English 4.7 KB
2025-12-09 09:36
Zelluna ASA: Cancellation of subsequent repair offering
English 1.8 KB
2025-12-09 08:22
Financial calendar
English 749 bytes
2025-12-08 18:36
Zelluna ASA - Mandatory notification of trade - Attachment: PDMR attachment.pdf
English 102.0 KB
2025-12-08 18:36
Zelluna ASA - Mandatory notification of trade
English 579 bytes
2025-12-08 13:52
Zelluna ASA: New share capital registered
English 2.4 KB
2025-11-28 07:50
Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financia…
English 4.2 KB
2025-11-27 08:35
Zelluna ASA: Disclosure of large shareholding
English 1.8 KB
2025-11-25 16:05
Zelluna ASA: Disclosure of large shareholding
English 1.4 KB
2025-11-25 12:09
ZELLUNA ASA: DISCLOSURE OF LARGE SHAREHOLDING
English 1.5 KB
2025-11-25 11:32
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025 - Attachm…
English 325.0 KB
2025-11-25 11:32
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025 - Attachm…
Norwegian 258.2 KB
2025-11-25 11:32
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025
English 1.5 KB
2025-11-04 13:04
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025 - Atta…
Norwegian 1014.6 KB
2025-11-04 13:04
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025
English 1.4 KB

Automate Your Workflow. Get a real-time feed of all Zelluna ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Zelluna ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Zelluna ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BELITE BIO, INC Logo
Clinical-stage biopharma developing therapies for retinal and metabolic diseases.
United States of America
BLTE
Benitec Biopharma Inc. Logo
A clinical-stage biotech developing genetic medicines to silence disease-causing genes.
United States of America
BNTC
BeOne Medicines Ltd. Logo
Global oncology company that discovers, develops, and delivers cancer treatments.
United States of America
ONC
BerGenBio Logo
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
Norway
BGBIO
Beximco Pharmaceuticals Ltd. Logo
Manufacturer of generic drugs, APIs, and specialized products for global markets.
Bangladesh
BXP
BeyondSpring Inc. Logo
Clinical-stage biopharma company developing immuno-oncology cancer therapies.
United States of America
BYSI
BGM Group Ltd. Logo
A holding company focused on technology and biopharmaceutical manufacturing.
United States of America
BGM
Bicara Therapeutics Inc. Logo
Clinical-stage biopharma developing dual-action biologics for solid tumors.
United States of America
BCAX
BICYCLE THERAPEUTICS PLC Logo
Clinical-stage biopharma developing a novel class of bicyclic peptide medicines.
United States of America
BCYC
BIFIDO. Co. Ltd Logo
Biotechnology firm developing human-derived Bifidobacterium for various products.
South Korea
238200

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.